- Home
- FDMT vs LRMR Comparison
FDMT vs LRMR Comparison
Compare FDMT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- LRMR
- Stock Information
- Founded
- FDMT 2013
- LRMR N/A
- Country
- FDMT United States
- LRMR United States
- Employees
- FDMT N/A
- LRMR N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- LRMR Health Care
- Exchange
- FDMT Nasdaq
- LRMR Nasdaq
- Market Cap
- FDMT 161.7M
- LRMR 183.8M
- IPO Year
- FDMT 2020
- LRMR N/A
- Fundamental
- Price
- FDMT $3.75
- LRMR $2.18
- Analyst Decision
- FDMT Buy
- LRMR Strong Buy
- Analyst Count
- FDMT 10
- LRMR 8
- Target Price
- FDMT $32.33
- LRMR $19.63
- AVG Volume (30 Days)
- FDMT 448.3K
- LRMR 1.3M
- Earning Date
- FDMT 05-08-2025
- LRMR 04-30-2025
- Dividend Yield
- FDMT N/A
- LRMR N/A
- EPS Growth
- FDMT N/A
- LRMR N/A
- EPS
- FDMT N/A
- LRMR N/A
- Revenue
- FDMT $23,000.00
- LRMR N/A
- Revenue This Year
- FDMT $13,097.30
- LRMR N/A
- Revenue Next Year
- FDMT N/A
- LRMR N/A
- P/E Ratio
- FDMT N/A
- LRMR N/A
- Revenue Growth
- FDMT N/A
- LRMR N/A
- 52 Week Low
- FDMT $2.24
- LRMR $1.61
- 52 Week High
- FDMT $28.93
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- FDMT 57.33
- LRMR 54.85
- Support Level
- FDMT $3.37
- LRMR $1.80
- Resistance Level
- FDMT $3.81
- LRMR $2.33
- Average True Range (ATR)
- FDMT 0.27
- LRMR 0.18
- MACD
- FDMT 0.03
- LRMR 0.04
- Stochastic Oscillator
- FDMT 82.02
- LRMR 90.00
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.